Kirsten M Williams1, Jennifer Holter-Chakrabarty2, Liza Lindenberg3, Quyen Duong2, Sara K Vesely2, Chuong T Nguyen4, Joseph P Havlicek4, Karen Kurdziel3, Juan Gea-Banacloche5, Frank I Lin6, Daniele N Avila7, George Selby2, Christopher G Kanakry7, Shibo Li2, Teresa Scordino2, Stephen Adler8, Catherine M Bollard9, Peter Choyke3, Ronald E Gress7. 1. Children's Research Institute, Children's National Health System, Washington, DC, USA. Electronic address: kmwillia@cnmc.org. 2. Stephenson Cancer Center, University of Oklahoma Health Sciences Center, Oklahoma City, OK, USA. 3. Molecular Imaging Branch, National Cancer Institute, and National Institutes of Health, Bethesda, MD, USA. 4. School of Electrical and Computer Engineering, University of Oklahoma, Norman, OK, USA. 5. Division of Infectious Diseases, Mayo Clinic Arizona, AZ, USA. 6. Cancer Imaging Program, National Cancer Institute, and National Institutes of Health, Bethesda, MD, USA. 7. Experimental Transplantation and Immunology Branch, National Cancer Institute, and National Institutes of Health, Bethesda, MD, USA. 8. Clinical Research Directorate/Clinical Monitoring Research Program, Leidos Biomedical Research, National Cancer Institute Campus at Frederick, Frederick, MD, USA. 9. Children's Research Institute, Children's National Health System, Washington, DC, USA.
Abstract
BACKGROUND: Haemopoietic stem-cell transplantation (HSCT) eradicates host haemopoiesis before venous infusion of haemopoietic stem cells (HSCs). The pathway to cellular recovery has been difficult to study in human beings because of risks associated with interventions during aplasia. We investigated whether 18F-fluorothymidine (18F-FLT) imaging was safe during allogenic HSCT and allowed visualisation of early cellular proliferation and detection of patterns of cellular engraftment after HSCT. METHODS: Eligible patients were aged 18-55 years, had high-risk haematological malignancies. All patients underwent myeloablation followed by HSCT. The imaging primary endpoint was detection of early subclinical engraftment after HSCT with 18F-FLT PET or CT. Imaging was done 1 day before and 5 or 9, and 28 days, and 1 year after HSCT. This study is registered with ClinicalTrials.gov, number NCT01338987. FINDINGS: Between April 1, 2014, and Dec 31, 2015, 23 patients were enrolled and assessable for toxic effects after completing accrual. 18F-FLT was not associated with any adverse events or delayed engraftment. 18F-FLT imaging objectively identified subclinical bone-marrow recovery within 5 days of HSC infusion, which was up to 20 days before engraftment became clinically evident. Quantitatively, 18F-FLT intensity differed significantly between myeloablative infusion before HSCT and subclinical HSC recovery (p=0·00031). 18F-FLT biodistribution over time revealed a previously unknown path of cellular recovery of haemopoiesis in vivo that mirrored fetal ontogeny. INTERPRETATION: 18F-FLT allowed quantification and tracking of subclinical bone-marrow repopulation in human beings and revealed new insights into the biology of HSC recovery after HSCT. FUNDING: National Institutes of Health, Ben's Run/Ben's Gift, Albert and Elizabeth Tucker Foundation, Mex Frates Leukemia Fund, Jones Family fund, and Oklahoma Center for Adult Stem Cell Research.
BACKGROUND: Haemopoietic stem-cell transplantation (HSCT) eradicates host haemopoiesis before venous infusion of haemopoietic stem cells (HSCs). The pathway to cellular recovery has been difficult to study in human beings because of risks associated with interventions during aplasia. We investigated whether 18F-fluorothymidine (18F-FLT) imaging was safe during allogenic HSCT and allowed visualisation of early cellular proliferation and detection of patterns of cellular engraftment after HSCT. METHODS: Eligible patients were aged 18-55 years, had high-risk haematological malignancies. All patients underwent myeloablation followed by HSCT. The imaging primary endpoint was detection of early subclinical engraftment after HSCT with 18F-FLT PET or CT. Imaging was done 1 day before and 5 or 9, and 28 days, and 1 year after HSCT. This study is registered with ClinicalTrials.gov, number NCT01338987. FINDINGS: Between April 1, 2014, and Dec 31, 2015, 23 patients were enrolled and assessable for toxic effects after completing accrual. 18F-FLT was not associated with any adverse events or delayed engraftment. 18F-FLT imaging objectively identified subclinical bone-marrow recovery within 5 days of HSC infusion, which was up to 20 days before engraftment became clinically evident. Quantitatively, 18F-FLT intensity differed significantly between myeloablative infusion before HSCT and subclinical HSC recovery (p=0·00031). 18F-FLT biodistribution over time revealed a previously unknown path of cellular recovery of haemopoiesis in vivo that mirrored fetal ontogeny. INTERPRETATION: 18F-FLT allowed quantification and tracking of subclinical bone-marrow repopulation in human beings and revealed new insights into the biology of HSC recovery after HSCT. FUNDING: National Institutes of Health, Ben's Run/Ben's Gift, Albert and Elizabeth Tucker Foundation, Mex Frates Leukemia Fund, Jones Family fund, and Oklahoma Center for Adult Stem Cell Research.
Authors: E F Srour; A Jetmore; F M Wolber; P A Plett; R Abonour; M C Yoder; C M Orschell-Traycoff Journal: Leukemia Date: 2001-11 Impact factor: 11.528
Authors: C Woolthuis; A Agool; S Olthof; R H J A Slart; G Huls; W M Smid; J J Schuringa; E Vellenga Journal: Bone Marrow Transplant Date: 2010-04-12 Impact factor: 5.483
Authors: Aurelie Kieusseian; Philippe Brunet de la Grange; Odile Burlen-Defranoux; Isabelle Godin; Ana Cumano Journal: Development Date: 2012-08-16 Impact factor: 6.868
Authors: G Sambuceti; M Massollo; C Marini; M Podestà; C Cassanelli; S Morbelli; F Fiz; A Buschiazzo; S Capitanio; C Augeri; G Curti; M Piana; F Frassoni Journal: Q J Nucl Med Mol Imaging Date: 2013-06 Impact factor: 2.346
Authors: Uday Popat; Rohtesh S Mehta; Katayoun Rezvani; Patricia Fox; Kayo Kondo; David Marin; Ian McNiece; Betul Oran; Chitra Hosing; Amanda Olson; Simrit Parmar; Nina Shah; Michael Andreeff; Partow Kebriaei; Indreshpal Kaur; Eric Yvon; Marcos de Lima; Laurence J N Cooper; Priti Tewari; Richard E Champlin; Yago Nieto; Borje S Andersson; Amin Alousi; Roy B Jones; Muzaffar H Qazilbash; Qaiser Bashir; Stefan Ciurea; Sairah Ahmed; Paolo Anderlini; Doyle Bosque; Catherine Bollard; Jeffrey J Molldrem; Julianne Chen; Gabriela Rondon; Michael Thomas; Leonard Miller; Steve Wolpe; Paul Simmons; Simon Robinson; Patrick A Zweidler-McKay; Elizabeth J Shpall Journal: Blood Date: 2015-03-16 Impact factor: 22.113
Authors: Mitchell E Horwitz; Nelson J Chao; David A Rizzieri; Gwynn D Long; Keith M Sullivan; Cristina Gasparetto; John P Chute; Ashley Morris; Carolyn McDonald; Barbara Waters-Pick; Patrick Stiff; Steven Wease; Amnon Peled; David Snyder; Einat Galamidi Cohen; Hadas Shoham; Efrat Landau; Etty Friend; Iddo Peleg; Dorit Aschengrau; Dima Yackoubov; Joanne Kurtzberg; Tony Peled Journal: J Clin Invest Date: 2014-06-09 Impact factor: 14.808
Authors: Ali Agool; Andor W J M Glaudemans; Hendrikus H Boersma; Rudi A J O Dierckx; Edo Vellenga; Riemer H J A Slart Journal: Eur J Nucl Med Mol Imaging Date: 2010-07-13 Impact factor: 9.236
Authors: Roni Tamari; Samantha Brown; Sean M Devlin; Satyajit Kosuri; Molly A Maloy; Doris M Ponce; Craig Sauter; Brian Shaffer; Parastoo Dahi; James W Young; Ann Jakubowski; Esperanza B Papadopoulos; Hugo Castro-Malaspina; Miguel-Angel Perales; Sergio A Giralt; Boglarka Gyurkocza Journal: Transplant Cell Ther Date: 2021-06-30
Authors: Ellison D Aldrich; Xiaolin Cui; Caroline A Murphy; Khoon S Lim; Gary J Hooper; C Wayne McIlwraith; Tim B F Woodfield Journal: Stem Cells Transl Med Date: 2021-08-13 Impact factor: 6.940